Neoadjuvant Chemotherapy Therapy Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer
Conditions: Locally Advanced Rectal Cancer Interventions: Drug: capecitabine; Drug: tislelizumab; Drug: thymalfasin; Radiation: long-term radiotherapy Sponsors: Beijing Friendship Hospital; Peking Union Medical College Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials

Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma
Conditions: Esophageal Squamous Cell Carcinoma; Neoadjuvant Chemoimmunotherapy; Adjuvant Therapy Interventions: Drug: Tislelizumab Sponsors: Guo Xufeng Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials

Neoadjuvant of Sintilimab Combined Weekly Metronomic Chemotherapy (PLOF) for Resectable Locally Advanced Gastric Cancer
Condition: Gastric Cancer Intervention: Drug: sintilimab+metronomic PLOF Sponsor: Huashan Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 26, 2023 Category: Research Source Type: clinical trials

Neoadjuvant of Sintilimab Combined Weekly Metronomic Chemotherapy (PLOF) for Resectable Locally Advanced Gastric Cancer
Conditions: Gastric Cancer Interventions: Drug: sintilimab+metronomic PLOF Sponsors: Huashan Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 26, 2023 Category: Research Source Type: clinical trials

Efficacy and Safety of SCRT Versus TNT in Older Patients With Locally Advanced Rectal Cancer
Conditions: Locally Advanced Rectal Cancer; Older People Interventions: Radiation: Short course radiotherapy; Drug: Adjuvant chemotherapy (optional); Procedure: Total mesorectal excision; Combination Product: Total neoadjuvant therapy Sponsors: Jules Bordet Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 25, 2023 Category: Research Source Type: clinical trials

Neoadjuvant Chemoimmunotherapy Followed By Radiation Or Organ Preservation Surgery In Laryngeal/Hypopharyngeal Cancer
Conditions: Larynx Cancer; Hypopharyngeal Cancer Interventions: Procedure: Surgery; Radiation: Radiation; Drug: Toripalimab Sponsors: Fudan University; Fudan University Eye Ear Nose and Throat Hospital; Shanghai Zhongshan Hospital; Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University; Ruijin Hospital; Xinhua Hospital, Shanghai Jiao Tong University School of Medicine Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials

Efficacy and Safety of the Proposed Biosimilar PERT-IJS Versus EU-Perjeta ® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer
Condition: HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients Interventions: Biological: PERT-IJS plus trastuzumab, carboplatin and docetaxel; Biological: Perjeta plus trastuzumab, carboplatin and docetaxel Sponsor: Biocon Biologics UK Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials